Apex (Suzhou) Medical Products Company

Apex (Suzhou) Medical Products Company specializes in single-use surgical devices for fluid management. These include surgical irrigation system nozzles for controlled fluid delivery during procedures, disposable irrigation/aspiration systems for operating environments, and closed-wound drainage receptacles for sterile fluid collection or evacuation in centesis procedures. The focus is on reusable and sterile single-use solutions to support surgical workflows.

The company is headquartered in Suzhou, China. Its location allows it to serve global markets while adhering to regional regulatory requirements, including those for medical devices in both China and international markets like the EU and the U.S.

Devices from Apex (Suzhou) Medical Products Company are listed in the EU’s EUDAQD (eudamed) database and the U.S. FDA’s Unique Device Identifier (UDI) database. These registries ensure traceability and compliance with EU Medical Device Regulations and U.S. FDA requirements, respectively, depending on the device’s classification and market authorization.

Under the EU Medical Device Regulations, Apex’s devices fall into Class I (typically low-risk, non-invasive items) or Class II/IIa (moderate-risk, where general or specific measures are required for safety and performance). The classification determines regulatory pathways, such as conformity assessment procedures, labeling requirements, and post-market surveillance obligations. For example, drainage receptacles or aspiration systems may require additional scrutiny due to their role in sterile procedures.

The classification depends on the device’s risk profile and intended use. Class I devices, like basic irrigation nozzles, pose minimal risk to patients and often require only general safety and performance requirements. In contrast, Class II/IIa devices—such as closed-wound drainage receptacles or aspiration systems—may involve more complex interactions with the body (e.g., fluid management in sterile environments) or require measures like clinical performance data to ensure safety and efficacy. The EU’s risk-based approach ensures appropriate oversight proportional to potential harm.